C. Reist

发表

Dosimetry of 131I-labeled 81C6 monoclonal antibody administered into surgically created resection cavities in patients with malignant brain tumors.

R. Coleman, A. Friedman, D. Bigner, 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Ticagrelor versus clopidogrel in patients with symptomatic peripheral artery disease and prior coronary artery disease: Insights from the EUCLID trial

K. Mahaffey, Manesh R Patel, L. Norgren, 2018, Vascular medicine.

Design and rationale for the Effects of Ticagrelor and Clopidogrel in Patients with Peripheral Artery Disease (EUCLID) trial.

K. Mahaffey, Manesh R Patel, L. Norgren, 2016, American heart journal.

Ticagrelor Compared With Clopidogrel in Patients With Prior Lower Extremity Revascularization for Peripheral Artery Disease

K. Mahaffey, Manesh R Patel, L. Norgren, 2017, Circulation.

Title : Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes

R. Califf, B. Lewis, R. Giugliano, 2022 .

In vitro and in vivo behavior of radiolabeled chimeric anti-EGFRvIII monoclonal antibody: comparison with its murine parent.

D. Bigner, S. Batra, M. Zalutsky, 1997, Nuclear medicine and biology.

Assessment of North American Clinical Research Site Performance During the Start-up of Large Cardiovascular Clinical Trials

Manesh R. Patel, Sunil V. Rao, R. Califf, 2021, JAMA network open.

Human IgG2 constant region enhances in vivo stability of anti-tenascin antibody 81C6 compared with its murine parent.

D. Bigner, M. Zalutsky, C. Reist, 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

Determinants of plasma vitamin D levels in patients with acute coronary syndromes

K. Mahaffey, A. Marian, N. Kleiman, 2011, European journal of clinical investigation.

Monoclonal Antibodies against EGFRvIII Are Tumor Specific and React with Breast and Lung Carcinomas and Malignant ( Â ¿ liornas 1

R. McLendon, P. Humphrey, D. Bigner, 2006 .

High-risk patients with acute coronary syndromes treated with low-molecular-weight or unfractionated heparin: outcomes at 6 months and 1 year in the SYNERGY trial.

R. Califf, E. Antman, H. White, 2005, JAMA.

Integrating ancillary studies in a large clinical trial: the design and rationale of the APEX library.

Manesh R. Patel, P. Armstrong, C. Granger, 2008, Contemporary clinical trials.

On-treatment analysis of the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT).

B. Lewis, R. Giugliano, E. Braunwald, 2016, American heart journal.

Dosimetry of 1311-Labeled81C6 Monoclonal Antibody Administered into Surgically Created Resection Cavities in Patients with Malignant Brain Tumors

D. Bigner, H. Friedman, M. Zalutsky, 2006 .

Antigen-based heteropolymers. A potential therapy for binding and clearing autoantibodies via erythrocyte CR1.

C. Reist, R. Taylor, W. Emlen, 1995, Arthritis and rheumatism.

Complement-opsonized IgG antibody/dsDNA immune complexes bind to CR1 clusters on isolated human erythrocytes.

E. L. Wright, C. Reist, R. Taylor, 1991, Clinical immunology and immunopathology.

Human IgG in immune complexes bound to human erythrocyte CR1 is recognized differently than human IgG bound to an erythrocyte surface antigen.

C. Reist, R. Taylor, J. Wright, 1993, Journal of immunological methods.

L-Amino acid oxidase (LOX) modulation of melphalan activity against intracranial glioma

D. Bigner, H. Friedman, O. Griffith, 1996, Cancer Chemotherapy and Pharmacology.

The class III variant of the epidermal growth factor receptor (EGFRvIII): characterization and utilization as an immunotherapeutic target.

D. Bigner, M. Zalutsky, G. Archer, 1998, Journal of neurovirology.

Effect of nesiritide in patients with acute decompensated heart failure.

L. Deckelbaum, V. Hasselblad, D. Atar, 2011, The New England journal of medicine.

125I-labeled anti-epidermal growth factor receptor-vIII single-chain Fv exhibits specific and high-level targeting of glioma xenografts.

I. Pastan, M. Zalutsky, C. Foulon, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

125 I-labeled Anti-Epidermal Growth Factor Receptor-vIII Single-Chain Fv Exhibits Specific and High-Level Targeting of Glioma Xenografts 1

I. Pastan, D. Bigner, M. Zalutsky, 1999 .

Radioiodination via D-amino acid peptide enhances cellular retention and tumor xenograft targeting of an internalizing anti-epidermal growth factor receptor variant III monoclonal antibody.

D. Bigner, M. Zalutsky, C. Foulon, 2000, Cancer research.

Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas.

R. McLendon, P. Humphrey, D. Bigner, 1995, Cancer research.

Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes.

R. Califf, B. Lewis, R. Giugliano, 2015, The New England journal of medicine.

Prognostic relevance of baseline pro- and anti-inflammatory markers in STEMI: an APEX AMI substudy.

V. Hasselblad, P. Armstrong, C. Granger, 2013, International journal of cardiology.

Tumor-specific anti-epidermal growth factor receptor variant III monoclonal antibodies: use of the tyramine-cellobiose radioiodination method enhances cellular retention and uptake in tumor xenografts.

M. Willingham, D. Bigner, S. Kurpad, 1995, Cancer research.

Antigens pre‐bound to the primate erythrocyte complement receptor via cross‐linked bispecific monoclonal antibody heteropolymers are rapidly cleared from the circulation

B. Croft, C. Reist, M. Combs, 1993, European journal of immunology.

Ticagrelor Versus Clopidogrel in Symptomatic Peripheral Artery Disease

K. Mahaffey, L. Norgren, F. Fowkes, 2017, The New England journal of medicine.

Prediction of One-Year Survival in High-Risk Patients with Acute Coronary Syndromes: Results from the SYNERGY Trial

R. Califf, E. Antman, H. White, 2008, Journal of General Internal Medicine.

Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: final baseline characteristics of the IMPROVE-IT study population.

R. Califf, R. Giugliano, E. Braunwald, 2014, American heart journal.

Reduction in Total Cardiovascular Events With Ezetimibe/Simvastatin Post-Acute Coronary Syndrome: The IMPROVE-IT Trial.

R. Giugliano, E. Braunwald, C. Cannon, 2016, Journal of the American College of Cardiology.

Heparin-associated anti-Xa activity and platelet-derived prothrombotic and proinflammatory biomarkers in moderate to high-risk patients with acute coronary syndrome

K. Mahaffey, S. Hazen, R. Becker, 2011, Journal of Thrombosis and Thrombolysis.

Radioiodination of Internalizing Monoclonal Antibodies Using N-Succinimidyl 5-Iodo-3-Pyridinecarboxylate '

D. Bigner, P. Garg, M. Zalutsky, 2006 .

Coordinated series of studies to evaluate characteristics and mechanisms of acute coronary syndromes in high-risk patients randomly assigned to enoxaparin or unfractionated heparin: design and rationale of the SYNERGY Library.

R. Califf, G. Stone, K. Mahaffey, 2004, American heart journal.

Rationale and design of the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure Trial (ASCEND-HF).

V. Hasselblad, R. Califf, C. O'connor, 2009, American heart journal.

Comparison of site-reported and core laboratory-reported creatine kinase-MB values in non-ST-segment elevation acute coronary syndrome (from the international trial SYNERGY).

R. Califf, E. Antman, L. Newby, 2009, The American journal of cardiology.

Complement-independent binding of microorganisms to primate erythrocytes in vitro by cross-linked monoclonal antibodies via complement receptor 1

J. Powers, W. Scheld, C. Reist, 1995, Infection and immunity.

Cross‐linked bispecific monoclonal antibody heteropolymers facilitate the clearance of human IgM from the circulation of squirrel monkeys

W. Scheld, C. Reist, D. Denny, 1994, European journal of immunology.

In vivo binding and clearance of circulating antigen by bispecific heteropolymer-mediated binding to primate erythrocyte complement receptor.

E. L. Wright, A. Otto, A Otto, 1992, Journal of immunology.

Use of heteropolymeric monoclonal antibodies to attach antigens to the C3b receptor of human erythrocytes: a potential therapeutic treatment.

E. L. Wright, D. Webb, C. Reist, 1991, Proceedings of the National Academy of Sciences of the United States of America.

Astatine-211 labeling of internalizing anti-EGFRvIII monoclonal antibody using N-succinimidyl 5-[211At]astato-3-pyridinecarboxylate.

D. Bigner, M. Zalutsky, C. Foulon, 1999, Nuclear medicine and biology.

Improved targeting of an anti-epidermal growth factor receptor variant III monoclonal antibody in tumor xenografts after labeling using N-succinimidyl 5-iodo-3-pyridinecarboxylate.

D. Bigner, M. Zalutsky, C. Reist, 1997, Cancer research.

Clinical Outcomes at 180 days in the ASCEND-HF Trial: Double-Blind, Placebo-Controlled, Multicenter Acute Study of Clinical Effectiveness of Nesiritide in Subjects With Decompensated Heart Failure

V. Hasselblad, R. Califf, K. Dickstein, 2011 .

Design and rationale for the Effects of Ticagrelor and Clopidogrel in Patients with Peripheral Artery Disease (EUCLID) trial.

K. Mahaffey, L. Norgren, I. Baumgartner, 2016, American heart journal.

Radioiodination of internalizing monoclonal antibodies using N-succinimidyl 5-iodo-3-pyridinecarboxylate.

D. Bigner, P. Garg, M. Zalutsky, 1996, Cancer research.

Reduction in Total Cardiovascular Events With Ezetimibe/Simvastatin Post-Acute Coronary Syndrome: The IMPROVE-IT Trial.

R. Giugliano, E. Braunwald, C. Cannon, 2016, Journal of the American College of Cardiology.